Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Carboxy or salt thereof only attached indirectly to the benzene ring

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514553000 - Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI

514557000 - Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)

514568000 - Benzene ring nonionically bonded

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514571000 Ether oxygen single bonded to carboxylic acid, percarboxylic acid or salt thereof through an acyclic carbon or acyclic carbon chain 22
Entries
DocumentTitleDate
20110201685Compositions - An ingestible particulate composition comprises: a) at least one compound selected from the group consisting of 2,4-dichlorobenzyl alcohol, amylmetacresol, cetylpyridinium chloride, hexitidine, hexylresorcinol, flurbiprofen, lidocaine, benzocaine, ibuprofen, paracetamol, pectin, menthol, and benzydamine; and b) one or more bioadhesive materials. Resulting particulate compositions have excellent flow characteristics, dust suppression, organoleptic properties and stability. They are highly suitable for administration direction into a patient's mouth, and ingested to alleviate the symptoms of a sore throat.08-18-2011
20130035392Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex - It pertains to selective inhibition of C3 convertase of the alternative pathway of complement as well as the previously claimed assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by C3 convertase activation of the alternative complement pathway, or the membrane attack complex, or both pathways. These diseases include, but are not limited to, paroxysmal nocturnal hemoglobinemia, rheumatoid arthritis, multiple sclerosis, malaria infection, Alzheimer disease, age related macular degeneration, and atherosclerosis.02-07-2013
20130035391Felbinac-Containing Transdermally Absorbable Preparation - An adhesive patch is a felbinac-containing transdermally absorbable preparation substantially free of a solubilizer for felbinac in a final preparation but still having high releasing of felbinac. The adhesive patch in which lidocaine and felbinac are formulated has the releasing of felbinac without losing the releasing of lidocaine. The felbinac-containing transdermally absorbable adhesive patch contains felbinac as an active component and lidocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In particular, the content of felbinac is from 0.1% to 10% by weight to the total weight of the drug-containing plaster and the content of lidocaine or the pharmaceutically acceptable salt thereof is from 0.01% to 20% by weight to the total weight of the drug-containing plaster.02-07-2013
20130041036FERULIC ACID AS FEED SUPPLEMENT IN BEEF CATTLE TO PROMOTE ANIMAL GROWTH AND IMPROVE THE MEAT QUALITY OF THE CARCASS AND THE MEAT - The present disclosure comprises a natural method of feed supplement to beef cattle, with a maize extract obtained from the nixtamalization process with a high content of ferulic acid and its salts, for a period of 30 days in the final phase of the feedlot. Use of this dietary supplementation enables an increase in carcass yield and meat quality that is not negatively affected as with a commercial β-agonist. In addition to the above effects, the effective supplementation of ferulic acid to cattle is shown to have antioxidant effects on fresh meat during its shelf life, which can lead to great benefits for the industrial meat market.02-14-2013
20100041758ADHESIVE PREPARATION - An adhesive preparation which has a pressure-sensitive adhesive layer comprising two components, i.e., a C1-4 alcohol ester of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-osocyclopentyl)ethyl]sulfanyl}butanoic acid and a silicone-based pressure-sensitive adhesive. This is an effective and safe preparation which is stable, shows little change in skin permability and release a drug not rapidly but continuously.02-18-2010
20100105775AMINO ACID SALTS OF PROSTAGLANDINS - The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.04-29-2010
20090234013PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY - The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.09-17-2009
20120232152TOPICAL IBUPROFEN FORMULATIONS - The present application relates to a topical formulation comprising ibuprofen, a hydroalcoholic based solvent system, a C09-13-2012
20130165518IBUPROFEN AND NARCOTIC ANALGESIC COMPOSITIONS - Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an akylhydroxy methylcellulose; a starch; and a lubricant. Also provided herein is a method of preparing a pharmaceutical tablet composition comprising: (a) Granulating ibuprofen, a narcotic analgesic, a first glidant, a first disintegrant, a binder, and starch to form granules wherein said granulating step comprises a wet granulation process; (b) blending the granules with extra-granular material comprised of a second glidant, a second disintegrant, a filler and starch to form a blend of granules and extra-granular material; and (c) compressing the blend into a tablet.06-27-2013
20120238630COMPOSITIONS COMPRISING NONSTEROIDAL ANTI - INFLAMMATORY DRUGS - The present invention describes liquid compositions comprising pharmaceutically active principles, like scarcely water-soluble, nonsteroidal anti-inflammatory drugs, in particular, but not exclusively, flurbiprofen (FP), processes for their manufacture and their therapeutic use. The liquid compositions comprising FP in association with natural polymers, like xyloglucans (XG), and pharmaceutically acceptable excipients like glycerol, are suitable to be used for pharmaceutical uses and are characterized by good tolerability, therapeutic efficacy, stability and palatability.09-20-2012
201102881751-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.11-24-2011
20090281190NOVEL ATTRACT AND KILL COMPOSITION FOR CONTROL OF PEST INSECTS - The invention relates to a composition and procedure to attract and kill insect pests. An insecticidal attract-and-kill composition comprising: an organic biodegradable matrix component from natural sources; an organic biodegradable ultraviolet light absorbent matrix component from natural sources; a biodegradable insecticidal or acaricidal compound; and a pheromonal or kairomonal attractant.11-12-2009
20090170949Method To Control Body Weight - The present invention relates to a method to treat obesity and/or a method to lose or control body weight. More specifically, the invention relates to the use of a compound inhibiting the sweet taste perception, preferably by inactivating the T1R3 receptor, for the preparation of a medicament to treat or prevent obesity and/or to treat or prevent diabetes and/or to lose or control body weight.07-02-2009
20100249237Non-Steroidal Anti-Inflammatory Drug Dosing Regimen - A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, or acetaminophen is provided. This method provides improved therapeutic effect, in particular pain relief, over extended time periods.09-30-2010
20100249236ADHESIVE AND PLASTER - An adhesive comprising a base with tackiness, an oil and ketoprofen, wherein the adhesive contains no L-menthol, the base is composed at least of a tacky composition comprising an elastomer and a tackifier and/or a tacky polymer containing an unsaturated monomer with a total of 5 or more carbon atoms as the monomer unit, the oil is an oil that is compatible with the tacky composition and the tacky polymer, and the oil content is 150-175 parts by weight with respect to 100 parts by weight as the total of the tacky composition and the tacky polymer.09-30-2010
20100249235ADMINISTRATION OF 3,5-DIIODOTHYROPROPIONIC ACID FOR STIMULATING WEIGHT LOSS, AND/OR LOWERING TRIGLYCERIDE LEVELS, AND/OR TREATMENT OF METABOLIC SYNDROME - The invention provides methods and compositions for stimulating weight loss or lowering triglyceride levels in an individual in need thereof. In methods of the invention, a pharmaceutical composition comprising a therapeutically effective amount of DITPA, and optionally one or a plurality of lipid lowering agents, is administered to an individual to stimulate weight loss, lower triglyceride and/or lipoprotein levels, and/or to treat one or more symptoms of metabolic syndrome.09-30-2010
20100249234METHODS OF REDUCING VIRULENCE IN BACTERIA - A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a phenylpropanoid-type inhibitory compound.09-30-2010
201000997681-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.04-22-2010
20100280122TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline.11-04-2010
20130190403ADMINISTRATION OF INTRAVENOUS IBUPROFEN TO TRAUMA PATIENTS - A method for treating human patients who require hospitalization for a trauma injury wherein the patients are intravenously administered a first dose of a therapeutically effective dose of ibuprofen intravenously as soon as possible after hospitalization is disclosed. The patients are further treated with intravenous ibuprofen at suitable dosing intervals to the human patient until (a) the patient no longer requires intravenous dosing of ibuprofen.07-25-2013
20090286882Cyclopropylacetic Acid Derivatives and Use Thereof - The present application relates to novel cyclopropylacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.11-19-2009
20080269334Highly Concentrated Pourable Aqueous Solutions Of Potassium Ibuprofen, Their Preparation And Their Use - Concentrated pourable potassium ibuprofen liquid compositions, and preparation and uses thereof are described. They are composed of (i) at least 60 wt % of potassium ibuprofen in dissolved form; (ii) water; (iii) one or more polyethylene glycols, (iv) optionally up to 5 wt % of at least one C10-30-2008
20090118372Inhibitors Of Biotin Protein Ligase - The present invention relates to a method for identifying an inhibitor of a biotin protein ligase. The method include the steps of (a) providing a substrate, wherein the substrate may be biotinylated; (b) contacting the substrate with biotin and a biotin protein ligase in the presence of a test compound; (c) determining the extent of biotinylation of the substrate by the biotin protein ligase in the presence of the test compound; and (d) identifying the test compound as an inhibitor of the biotin protein ligase by a reduction in the biotinylation of the substrate in the presence of the test compound as compared to the extent of biotinylation of the substrate in the absence of the test compound.05-07-2009
20090048345IMMEDIATE RELEASE AND SUSTAINED RELEASE IBUPROFEN DOSING REGIMEN - A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.02-19-2009
20110230561MEDICAL ADHESIVE COMPOSITIONS - A medical adhesive composition comprising, based upon the total weight of the composition, from about 50 wt. % to about 99.9 wt. % of one or more α-cyanoacrylate monomers and from about 0.1 wt. % to about 5 wt. % of one or more non-steroidal anti-inflammatory drugs (NSAIDs). Suitable NSAIDs include ibuprofen and acetaminophen. The resulting compositions provide enhances fibroblast proliferation and reduced cytotoxicity compared to compositions that do not contain NSAID.09-22-2011
20090105345AMIDE LINKED MODULATORS OF Gamma-SECRETASE - The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, R04-23-2009
20090105344BIPHENYL CARBOXYLIC ACIDS AND DERIVATIVES THEREOF04-23-2009
20090156681COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.06-18-2009
20090203793COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed as Formula (I).08-13-2009
20100234463Method for Identifying Modulators of Gamma Secretase or Notch - The present invention relates to methods for high throughput screening to identify selective modulators of γ-secretase. Such modulators selectively block γ-secretase activity without affecting Notch cleavage and signaling. Said methods employ the use of high content screening methodologies to measure and quantify the translocation of the Notch intracellular domain (NICD) between the nucleus and cytoplasm in cells and the activation of Notch.09-16-2010
20130217774NOVEL PROCESS FOR PREPARING DEXIBUPROFEN READY TO COMPRESS GRANULES - Preparing a dexibuprofen pharmaceutical formulation in the form of granules that can be directly compressed into tablets. The process consists of two steps: (i) preparation of base granules, and (ii) blending base granules with a compression aid. The process of preparing base granules involves use of liquid bed granulator with top spray method, or slugging by roll compaction. The granules prepared by using both the methods showed improved compressibility and flowability compared to granules prepared by conventional granulation process using rapid mixer granulator. The ready-to-compress granules prepared by the process show no signs of sticking when compressed on a high-speed commercial scale tablet compression machine.08-22-2013
20100184861METHOD AND APPARATUS FOR DRY GRANULATION - The invention provides, inter alia, a method for producing granules from a powder, characterized in that compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the other granules by entraining the fine particles and/or small granules in a gas stream. Also provided are apparatus for use in the process and tablets formed by compression of the resultant granules.07-22-2010
20090062394TRANSDERMAL DELIVERY OF KETOPROFEN POLAR DERIVATIVES - A topical or transdermal composition including a polar derivative of ketoprofen and a pharmaceutically acceptable topical or transdermal carrier, wherein the polar derivative of ketoprofen comprises a polarity that is greater than that of ketoprofen.03-05-2009
20110086921Novel Polymorphic Forms of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid - Polymorphic forms 1 and 2 of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such polymorphs and the use of such polymorphs in medicine.04-14-2011
20110124730ORAL PHARMACEUTICAL SUSPENSION COMPRISING PARACETAMOL AND IBUPROFEN - The present invention relates to an oral pharmaceutical suspension comprising paracetamol and ibuprofen. The invention also relates to a method of treating perioperative or postoperative pain by administering to a subject a therapeutically effective amount of oral pharmaceutical suspension comprising paracetamol and Ibuprofen.05-26-2011
20100240758EXTERNAL PREPARATION FOR PERCUTANEOUS ADMINISTRATION CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC - An external preparation for percutaneous administration which contains a light-sensitive nonsteroidal anti-inflammatory analgesic and a UVA-shielding agent which inhibits the analgesic to cause light toxicity and a light allergy. This external preparation for percutaneous administration, which contains a nonsteroidal anti-inflammatory analgesic, can be prevented, with higher certainty, from causing the hypersensitivity to light attributable to light toxicity and a light allergy.09-23-2010
20090312426PROCESS OF PREPARING DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID - Compounds represented by formula (I):12-17-2009
20110245346NOVEL POLYMORPHS AND SALTS - Novel polymorphic forms and salts of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease.10-06-2011
201000694964-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.03-18-2010
20110152373HAIR GROWTH PROMOTING AGENT CONTAINING 15,15-DIFLUOROPROSTAGLANDIN F2ALPHA DERIVATIVE AS ACTIVE INGREDIENT - The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F06-23-2011
20120202882PERMEATION ENHANCERS FOR TOPICAL FORMULATIONS - A composition to be used as a permeation enhancer is provided. The composition may be added to topical cosmetics or pharmaceutical formulations that are topically applied. The composition comprises about 0.05-5% w/w of one or more phospholipids, 1-20% w/w of one or more oils having essential fatty acids, behenic acid, and oleic acid, 0.1-3% w/w of one or more skin lipids, and 1-10% w/w of a butter having linoleic acid and linolenic acid. One of the oils used in the composition is Pracaxi oil.08-09-2012
20110039934PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2- HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID - Compounds according to formula (IA):02-17-2011
20110028557TREATING PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.02-03-2011
20110028556TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.02-03-2011
20080280985Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes - This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a compound including an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer includes two groups selected from selenium, sulfur, S(O) and S(O)11-13-2008
20110054033METHODS OF USING ABSCISIC ACID FOR AMELIORATING HYPERTENSION AND VASCULAR INFLAMMATION - Methods and compositions for treating or preventing hypertension or vascular inflammation are described. These methods of the invention involve the administration of abscisic acid (ABA) to subjects in need thereof.03-03-2011
20110003895Pharmacology of Visual Cycle Modulators - Described herein are methods for the treatment of an ophthalmic disease or disorder comprising the administration of non-retinoid visual cycle modulators.01-06-2011
20090176884PHARMACEUTICAL SUSPENSION COMPOSITION - An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.07-09-2009
20090176883TRPA1 Antagonists - Compounds of formula (I)07-09-2009
20100137443Ibuprofen for Topical Administration - Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl)propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide.06-03-2010
20090215901Methods for treatment of nocturia - A method for the treatment of nocturia which consists of administering to a mammal in need of such treatment a therapeutically effective amount of a nonsteroidal anti-inflammatory drug consisting of loxoprofen or a pharmacologically acceptable salt thereof, wherein the mammal is a human who has a neurogenic bladder.08-27-2009
20100311839Burst Drug Release Compositions - A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation.12-09-2010
20090012173Method for treatment of nocturia - A method for treatment of nocturia by administering to a mammal, such as a human, in need of such treatment, a therapeutically effective amount of loxoprofen or a pharmacologically acceptable salt thereof.01-08-2009
20120004308METHOD FOR OBTAINING SOLID MICRO- OR NANOPARTICLES - The invention provides a novel method for obtaining solid micro- or nanoparticles with a homogeneous structure. A method is provided for obtaining solid micro- or nanoparticles with a homogeneous structure having a particle size of less than 10 μm where the processed solid compound has the natural, crystalline, amorphous, polymorphic and other features associated with the starting compound. In accordance with the invention a method which also makes it possible to obtain solid micro- or nanoparticles with a substantially spheroidal morphology is provided.01-05-2012
20090209649ALPHA-GLUCOSIDASE INHIBITOR, INHIBITOR FOR BLOOD GLUCOSE LEVEL ELEVATION AND FUNCTIONAL FOOD CONTAINING TRICAFFEOYLALDARIC ACID AND METHOD FOR PRODUCING TRICAFFEOYLALDARIC ACID - Components that demonstrate an α-glucosidase inhibitory activity and hyperglycemic inhibitory activity have clearly been provided from among the components included in Yacon. The present inventors found that as a result of screening for a strong anti-oxidant component in a Yacon aerial portion extract, an antioxidant activity was converged in a DIAION HP-20 column chromatography 50% methanol-eluted fraction of hot water extract. Thus, since a previously unidentified high-content component was confirmed, the present inventors conducted purification thereof, and thereby separated TCAA. As a result, this TCAA was found to be the component that demonstrates the α-glucosidase inhibitory activity and hyperglycemic inhibitory activity.08-20-2009
20120010294COMPOSITIONS AND METHODS FOR THE INHIBITION OF MUSCLE CONTRACTION - Compositions and methods for the inhibition of muscle contraction are disclosed. In one aspect, the present application discloses pharmaceutical compositions comprising analgesic agents for the inhibition of muscle contraction. In another aspect, the application discloses methods for the prophylactic intervention against premature pain associated with the filling of the urinary bladder of a subject. In yet another aspect, the application discloses methods for the prophylactic intervention against muscle pain associated with physical activity.01-12-2012
20110028558TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN - Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.02-03-2011
20110166233COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.07-07-2011
20110166234MEDICINAL PRODUCT AND TREATMENT - The use of paracetamol and ibuprofen in the preparation of a medicament for treating osteoarthritis or rheumatoid arthritis, wherein the medicament comprises a combination composition having approximately 125 mg to approximately 150 mg ibuprofen and approximately 475 mg to approximately 500 mg paracetamol.07-07-2011
201200221631-(2-FLUOROBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES FOR THE THERAPY OF PRION DISEASES - Derivatives of 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid are useful for the prevention and/or treatment of prion diseases in animals and humans.01-26-2012
20100048710Methods and Compositions for Modulating Muscle Fat in Livestock - The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in livestock animals. In particular, the present invention relates to compositions and methods for the use of non-steroidal antiinflammatory drugs to preferentially increase the amount of intramuscular adipose tissue in cattle.02-25-2010
20100144884NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel 3-phenyl acrylic acid compounds have the following general formula (I):06-10-2010
20120208887STABLE, LIQUID, READY-TO-USE KETOPROFEN FORMULATIONS - Stable, liquid, ready-to-use ketoprofen formulation for parenteral administration are provided. In some embodiments, the formulation comprises ketoprofen solubilized in a solely aqueous solvent comprising a buffering agent, wherein the composition has a pH of about 5.5 to about 6.5.08-16-2012
20080312327Organic Compositions - Provided is an improved liquid composition for the treatment of surfaces, preferably the skin and/or hair in order to provide a cleaning and/or sanitizing effect thereto, which necessarily comprises: one or more detersive surfactants selected from anionic, nonionic, cationic, and amphoteric surfactants; a first biocidal constituent(s) which provide a biocidal effect in conjunction with at least one or more second biocidal constituent(s) selected from benzoic acid, benzoic acid derivatives and salts thereof or farnesol, one or more pH adjusting constituents, optionally one or more organic solvents, hydrotropes, and further additive constituents, and water. In preferred embodiments the hydrotrope and/or organic solvents are desirably excluded from the compositions, and the composition is thickened. The compositions are particularly useful as a hand wash composition, body wash or shampoo.12-18-2008
20110184066Ketoprofen Lysine Salt-Containing Aqueous Patch - A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch includes as a main active ingredient a ketoprofen lysine salt completely dissolved in a paste including not glycerin but a polyethylene glycol having an average molecular weight of 1000 or less. In the ketoprofen lysine salt-containing aqueous patch, the polyethylene glycol having an average molecular weight of 1000 or less is one or more polyethylene glycols selected from the group consisting of Polyethylene glycol 200, Polyethylene glycol 400, Polyethylene glycol 600, and Polyethylene glycol 1000.07-28-2011
20120136060IMMEDIATE RELEASE AND SUSTAINED RELEASE IBUPROFEN DOSING REGIMEN - A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.05-31-2012
20120220662PHYTOCEUTICAL COMPOSITIONS FOR PETS - This invention comprises applying phytoceutical compositions to pets, which given their sedentary life and nutrition, are susceptible to a higher prevalence of cancer and degenerative diseases. The compounds contained in said compositions frequently have anti-oxidizing properties acting to inhibit harmful reactions of free radicals; free radicals are often a cause of cancer. Said compositions comprise extracts or concentrates obtained from the enzymatic or alkaline hydrolysis of several plant sources, containing effective concentrations of two or more phenolic compounds, such as ferulic acid, coumaric acid, caffeic acid, protocathecoic acid, and vanillic acid.08-30-2012
20120220661METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF - A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.08-30-2012
20120259018COMPOSITION OF DEXIBUPROFEN TRANSDERMAL HYDROGEL - Stable non-alcoholic transdermal hydrogel of dexibuprofen was prepared by using a simple manufacturing process, and the experimental trials showed that the pH modifying agent, antioxidant and water miscible solvent are the essential excipients to obtain stable non-alcoholic transdermal hydrogel of dexibuprofen. The dexibuprofen hydrogel prepared using carbopol as a gelling polymer produced an opaque gel, whereas hydrogel prepared using hyroxypropyl methylcellulose (HPMC) as a gelling polymer produced a transparent gel. There was no significant changes observed with respect to physical description, pH, assay and particularly to the related substance values when the hydrogels were subjected to the stability study at accelerated condition (40° C./75% RH) for 3 months in laminated tubes.10-11-2012
20100234465Administration of Intravenous Ibuprofen - An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia.09-16-2010
20100234464COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - 3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid, 4-(2,6-Dimethylbenzyloxy)-phenylacetic acid, and their pharmaceutically acceptable salts are useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.09-16-2010
20120277318NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR COUGH - The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.11-01-2012
20110281949METHODS AND COMPOSITIONS FOR TREATING NEURONAL DAMAGE AND MODULATING TRANSIENT RECEPTOR POTENTIAL CHANNELS - Use of alkyl phenol and monocyclic monoterpene-derived compounds in the treatment of neuronal damage and in inhibiting activity of TRPC and non-thermo-TRPM channels, and use of bicyclic monoterpene-derived compounds in activating TRPC and non-thermo-TRPM channels.11-17-2011
20110319492MANUFACTURE OF TABLETS FROM ENERGY-APPLIED POWDER BLEND - The present invention features a process for making tablets containing one or more pharmaceutically active agent(s) and one or more binder(s), the method including the steps of (i) applying energy to a powder blend comprising the pharmaceutically active agent(s) and the binder(s) for a sufficient period of time to activate the binder(s) within the powder blend and (ii) forming a predetermined amount of the energy-applied powder blend into the tablets.12-29-2011
20120329875Ibuprofen for Topical Administration - Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl) propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide.12-27-2012
20130172419POLYMER COMPOSITES OF SILICONE IONOMERS - A polymer composite composition wherein at least one of the constituents is a silicone ionomer and the other constituent is polymer.07-04-2013
201102637111-(2-FLUOROBIPHENYL-4-YL)-ALKYL CARBOXYLIC ACID DERIVATIVES FOR THE THERAPY OF TRANSTHYRETIN AMYLOIDOSIS - Derivatives of 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid are capable of stabilizing the tetrameric native state of transthyretin for the prophylaxis and treatment of amyloidosis.10-27-2011
20080214669Composition and Method For Treating Hyperpigmented Skin - An improved cosmetic and dermatological composition and a method for treating hyperpigmented skin is disclosed. The composition demonstrates an enhanced ability to lighten mammalian skin color, and is nontoxic and nonirritating. The composition comprises a hydroxycinnamic acid or a methoxycinnamic acid dissolved in a compound having one or more hydroxy groups, like a monoC09-04-2008
20080200549PHARMACEUTICAL COMPOSITION OF IBUPROFEN AND PARACETAMOL AND METHODS OF USING THE SAME - A combination pharmaceutical composition for the treatment of pain comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol, and a method for alleviating pain in a patient comprising administering to the patient a pharmaceutical composition comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol.08-21-2008
20100286278Composition comprising an HDAC inhibitor in combination with a retinoid - The present invention is directed to compositions which contain a combination of at least one histone deacetylase inhibitor (HDAC inhibitor) and a retinoid. The composition is in particular a cosmetic preparation. It was found that the combination of an HDAC inhibitor and retinol or a derivative thereof is in particular useful for treating wrinkles but also for thickening the epidermis and for improving hair growth.11-11-2010
20110275718Pharmaceutical composition of ibuprofen and paracetamol and methods of using the same - A combination pharmaceutical composition for the treatment of pain comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol, and a method for alleviating pain in a patient comprising administering to the patient a pharmaceutical composition comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol.11-10-2011
20120283329S ISOMERS OF ALPHA-METHYL HYDROCINNAMIC ACID FOR THE TREATMENT OF BLOOD DISORDERS - The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an S-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets. Accordingly, one aspect of the present invention relates to administration of S-isomer of alpha-methyl-hydrocinnamic acid, e.g., by oral administration to a subject for the treatment of blood disorders, for example but not limited to, hemaglobinaphthy, thalassemia and aplastic anemia. In some embodiments, the oral pharmaceutical formulation comprising an S-isomer of -α-methyl-hydrocinnamic acid can be used to increase red blood cell proliferation, or increase the proliferation of hemoglobin-expressing cells in a subject in need thereof, e.g., a subject having a blood deficiency such as a subject undergone chemotherapy or radiation exposure or radiation therapy. In some embodiments, a formulation comprising an S-isomer of alpha-methyl-hydrocinnamic acid (ST7S) can be used to simulate myelopiesis or erythropoiesis in a subject in need thereof.11-08-2012
20120095102Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof - The present invention relates to salts of 3-pentylphenylacetic acid and their pharmaceutical uses. Particular aspects of the invention relate to the use of those salts in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention and treatment of (i) blood disorders, (ii) renal disorders and renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.04-19-2012

Patent applications in class Carboxy or salt thereof only attached indirectly to the benzene ring

Patent applications in all subclasses Carboxy or salt thereof only attached indirectly to the benzene ring